Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Autus Valve Pivotal Study
NCT05006404
Recruiting
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-i... Read More
Gender:
All
Ages:
Between 18 months and 16 years
Trial Updated:
06/04/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Congenital Heart Disease
Register for Updates
STEM-Parkinson's Disease
NCT04797611
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Inland Northwest Research, Spokane, Washington
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
Register for Updates
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022
Recruiting
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram [mg] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), follo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Providence Regional Cancer Partnership, Everett, Washington
Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Primary Sclerosing Cholangitis in Children
NCT04181138
Recruiting
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: Collect medical and other data to learn more about PSC, how it progresses, and... Read More
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
06/04/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Seattle Cancer Care Alliance, Seattle, Washington
Conditions: Metastatic Urothelial Cancer
Register for Updates
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
NCT03073967
Recruiting
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once week... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
06/04/2024
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: HSV Infection
Register for Updates
Biliary Atresia Study in Infants and Children
NCT00345553
Recruiting
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To identify polymorphisms that may be important in disease progression such as HLA polymorphisms; To characterize the natural history of the older, non-... Read More
Gender:
All
Ages:
Between 6 months and 20 years
Trial Updated:
06/04/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Biliary Atresia
Register for Updates
A Prospective Database of Infants With Cholestasis
NCT00061828
Recruiting
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediat... Read More
Gender:
All
Ages:
6 months and below
Trial Updated:
06/04/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Biliary Atresia, Neonatal Cholestasis
Register for Updates
Positive Peers Intervention Clinical Trial
NCT06388109
Recruiting
The goal of this clinical trial is to learn if the Positive Peers mobile app intervention increases rates of viral suppression in young (13-34 y/o) persons with HIV. Does use of the Positive Peers app improve viral suppression among young minority persons with HIV? What user characteristics are associated with a) viral suppression, b) retention in care, and c) perceived HIV-related stigma? Participants will: download the mobile app onto their personal smartphone Use the mobile app as they fin... Read More
Gender:
All
Ages:
Between 13 years and 34 years
Trial Updated:
06/03/2024
Locations: UW Madison Clinic at Harborview, Seattle, Washington
Conditions: HIV Infections
Register for Updates
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
NCT06357832
Recruiting
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatmen... Read More
Gender:
All
Ages:
Between 22 years and 68 years
Trial Updated:
06/03/2024
Locations: ClearPath Psychiatry, Seattle, Washington
Conditions: Major Depressive Disorder
Register for Updates
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415
Recruiting
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: University of Washington (UW) Medical Center, Seattle, Washington
Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/03/2024
Locations: Core Clinical Research, Everett, Washington
Conditions: Major Depressive Disorder
Register for Updates